SG11201811796SA - Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same - Google Patents
Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising sameInfo
- Publication number
- SG11201811796SA SG11201811796SA SG11201811796SA SG11201811796SA SG11201811796SA SG 11201811796S A SG11201811796S A SG 11201811796SA SG 11201811796S A SG11201811796S A SG 11201811796SA SG 11201811796S A SG11201811796S A SG 11201811796SA SG 11201811796S A SG11201811796S A SG 11201811796SA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- same
- optically active
- phenol derivative
- pyranochromenyl phenol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
[] The present invention relates to pyranochromenylphenol derivatives having different efficacies depending on the direction of optical activity and a pharmaceutical composition including the same, and in the pyranochromenylphenol derivatives, an R-enantiomer has excellent anti-diabetic efficacy by suppressing a rise in blood sugar and an S-enantiomer has excellent anti-obesity efficacy by suppressing an increase in body weight. [Representative Drawing] FIG. 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160081674 | 2016-06-29 | ||
| PCT/KR2017/006863 WO2018004263A1 (en) | 2016-06-29 | 2017-06-29 | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811796SA true SG11201811796SA (en) | 2019-02-27 |
Family
ID=60787377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811796SA SG11201811796SA (en) | 2016-06-29 | 2017-06-29 | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20190152984A1 (en) |
| EP (2) | EP4023651B1 (en) |
| JP (2) | JP2019520381A (en) |
| KR (1) | KR102388965B1 (en) |
| CN (1) | CN109476676B (en) |
| AU (1) | AU2017287746B2 (en) |
| BR (1) | BR112018077392A2 (en) |
| CA (1) | CA3028954C (en) |
| DK (1) | DK4023651T3 (en) |
| ES (2) | ES2929931T3 (en) |
| IL (1) | IL263826B2 (en) |
| MX (1) | MX2018016361A (en) |
| PL (2) | PL3480200T3 (en) |
| SG (1) | SG11201811796SA (en) |
| TW (1) | TWI731998B (en) |
| WO (1) | WO2018004263A1 (en) |
| ZA (1) | ZA201900121B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3524609T3 (en) * | 2016-10-04 | 2021-12-27 | Glaceum, Inc. | Process for the preparation of 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivatives, optical isomers thereof, and intermediates of the process |
| KR20200105198A (en) | 2019-02-28 | 2020-09-07 | 주식회사 글라세움 | Pharmaceutical composition for the prevention or treatment of neurological diseases |
| WO2022260434A1 (en) | 2021-06-08 | 2022-12-15 | 주식회사 글라세움 | Pharmaceutical composition for preventing or treating autoimmune disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160964A0 (en) * | 2001-10-11 | 2004-08-31 | Kaneka Corp | Peroxisome proliferator activated receptor ligand and process for producing the same |
| TW200513194A (en) * | 2003-07-31 | 2005-04-16 | Kaneka Corp | Fat and oil processed composition for prevention and/or amelioration of life-style related disease |
| WO2007058480A1 (en) * | 2005-11-16 | 2007-05-24 | Md Bioalpha Co., Ltd. | Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin |
| KR102344479B1 (en) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | Pyranochromenylphenol derivatives and a pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
| KR101742274B1 (en) | 2014-12-31 | 2017-06-01 | 주식회사 과학기술분석센타 | Apparatus of water quality of integrated management system of small scale water supply facility |
| PL3524609T3 (en) * | 2016-10-04 | 2021-12-27 | Glaceum, Inc. | Process for the preparation of 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivatives, optical isomers thereof, and intermediates of the process |
-
2017
- 2017-06-29 CN CN201780040744.8A patent/CN109476676B/en active Active
- 2017-06-29 ES ES17820539T patent/ES2929931T3/en active Active
- 2017-06-29 TW TW106121811A patent/TWI731998B/en active
- 2017-06-29 PL PL17820539.9T patent/PL3480200T3/en unknown
- 2017-06-29 KR KR1020170082391A patent/KR102388965B1/en active IP Right Grant
- 2017-06-29 BR BR112018077392-1A patent/BR112018077392A2/en active Search and Examination
- 2017-06-29 MX MX2018016361A patent/MX2018016361A/en unknown
- 2017-06-29 AU AU2017287746A patent/AU2017287746B2/en active Active
- 2017-06-29 EP EP22153273.2A patent/EP4023651B1/en active Active
- 2017-06-29 WO PCT/KR2017/006863 patent/WO2018004263A1/en unknown
- 2017-06-29 US US16/313,777 patent/US20190152984A1/en not_active Abandoned
- 2017-06-29 ES ES22153273T patent/ES2964146T3/en active Active
- 2017-06-29 CA CA3028954A patent/CA3028954C/en active Active
- 2017-06-29 JP JP2018569103A patent/JP2019520381A/en active Pending
- 2017-06-29 EP EP17820539.9A patent/EP3480200B1/en active Active
- 2017-06-29 SG SG11201811796SA patent/SG11201811796SA/en unknown
- 2017-06-29 PL PL22153273.2T patent/PL4023651T3/en unknown
- 2017-06-29 DK DK22153273.2T patent/DK4023651T3/en active
-
2018
- 2018-12-19 IL IL263826A patent/IL263826B2/en unknown
-
2019
- 2019-01-08 ZA ZA2019/00121A patent/ZA201900121B/en unknown
-
2020
- 2020-08-06 JP JP2020133796A patent/JP7036871B2/en active Active
- 2020-12-08 US US17/114,584 patent/US11332475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015106269A3 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| MX2020000333A (en) | Anti-egfr antibody drug conjugate formulations. | |
| WO2015165413A8 (en) | New stable antibody-drug conjugate, preparation method therefor, and use thereof | |
| WO2012103038A3 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| MX2023003124A (en) | Ophthalmic pharmaceutical compositions and uses relating thereto. | |
| WO2017127835A3 (en) | Aqueous formulations and methods of preparation and use thereof | |
| BR112018016729A2 (en) | new thiophene compound substituted at positions 2,3,5, used as a protein kinase inhibitor | |
| EP4173615A3 (en) | Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems | |
| HRP20211824T1 (en) | Modulators of complement activity | |
| EP3067059A4 (en) | Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| WO2013171764A3 (en) | Ophthalmic formulations | |
| SG11201811796SA (en) | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same | |
| MY190011A (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| EA201690323A1 (en) | METHODS OF TREATING EAR DISEASES IN CHILDREN | |
| MX2016015211A (en) | Topical formulations and uses thereof. | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| EP3701970A4 (en) | Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2014116015A3 (en) | Composition for preventing alzheimer's disease, containing purple bamboo salt, and method for preparing purple bamboo salt | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |